Accession Number:

AD1166364

Title:

NY-ESO-1-specific TCR-engineered T-cell Immunotherapy for Triple Negative Breast Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

METHODIST HOSPITAL HOUSTON TX

Personal Author(s):

• Wang, Rong
• Chang, Jenny
• ,

Report Date:

2021-10-01

Pagination or Media Count:

26

Abstract:

Triple negative breast cancer TNBC is the most aggressive and difficultly treated subtype of metastatic breast cancer, with very limited treatment option due to lack of expression of estrogen receptors ERs, progesterone receptors PRs, or human epidermal growth factor receptor 2 HER2. Cancer immunotherapy is becoming a promising approach for cancer treatment with little or controllable side effect. We hypothesize that treatment of TNBC patients with NY-ESO-1 TCR-transduced T cells is safe and will result in tumor regression and clinical benefits.

Descriptors:

• health services
• medical personnel
• breast cancer
• blood
• chemistry
• immunity
• biomedical research
• clinical trials
• immunotherapy
• neoplasms
• viruses
• covid-19
• institutional review board
• proteins
• therapy
• virion
• abstracts

Subject Categories:

• Anatomy and Physiology
• Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]